A Multi-Center, Prospective, Observational Study to Evaluate the Therapeutic Effectiveness and Safety of an Olmesartan/Amlodipine Plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia
- Authors
- Lee, Bong-Ki; Kim, Byeong-Keuk; Park, Jae Hyoung; Chung, Jong-Won; Park, Chang Gyu; Kim, Jin Won; Kim, Young Dae; Park, Woo-Jung; Kim, Sang-Hyun; Cha, Jae-Kwan; Kim, Cheol Ho; Rha, Seung-Woon; Hong, Young Joon; Shin, Mi-Seung; Cho, Seong Wook; Sung, Young-Hee; Lee, Kiheon; Yu, Jae-Myung; Ryu, Dong-Ryeol; Yu, Sungwook; Song, Tae-Jin; Ku, Bon D; Kim, Sin-Gon; Park, Hwan-Cheol; Cho, Deok-Kyu; Kim, Byung-Su; Han, Seong-Woo; Park, Sung-Ji; Park, Gyung-Min; Han, Kyoo-Rok
- Issue Date
- Jan-2025
- Publisher
- MDPI AG
- Keywords
- blood pressure; dyslipidemia; hypertension; low-density lipoprotein cholesterol; observational study; single-pill combination
- Citation
- Journal of Clinical Medicine, v.14, no.2, pp 1 - 15
- Pages
- 15
- Indexed
- SCIE
SCOPUS
- Journal Title
- Journal of Clinical Medicine
- Volume
- 14
- Number
- 2
- Start Page
- 1
- End Page
- 15
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/206580
- DOI
- 10.3390/jcm14020308
- ISSN
- 2077-0383
2077-0383
- Abstract
- Introduction: This study assessed the therapeutic effectiveness of a single-pill combination (SPC) of olmesartan/amlodipine plus rosuvastatin for blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) in patients with hypertension and dyslipidemia. Methods: Adult patients with hypertension and dyslipidemia who were decided to be treated with the study drug were eligible. The primary endpoint was the proportion of patients who achieved BP, LDL-C and both BP and LDL-C treatment goals at weeks 24–48. Secondary endpoints were assessed at weeks 24–48 and included changes in BP and LDL-C levels from baseline; the proportion of patients who achieved treatment goals who were initially classified as uncontrolled at baseline; changes and percent changes in lipid parameters; changes in both BP and LDL-C levels among patients who reached treatment goals who were followed for more than 24 weeks; and the overall safety profile. Results: A total of 5476 patients were enrolled, and 4411 patients comprised the effectiveness evaluation set. The proportions of patients who reached the treatment goals for BP, LDL-C levels, and both BP and LDL-C levels were 67.93% [95% confidence interval (CI) 66.52–69.32], 80.19% [95% CI 78.85–81.49], and 58.07% [95% CI 56.43–59.7], respectively. Secondary endpoints showed statistically significant changes. Overall, the treatment was well tolerated. Conclusions: The treatment of patients with hypertension and dyslipidemia with the olmesartan/amlodipine plus rosuvastatin SPC was associated with significant decreases in SBP/DBP and LDL-C levels, and a high proportion of patients achieved the BP and LDL-C treatment goals. The finding of this study is worthwhile in that this study evaluated the effectiveness and safety in a broad patient population representative of those seen in everyday clinical practice.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.